Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Corp to present Alzheimer’s research data at Paris conference

Summit Corp to present Alzheimer’s research data at Paris conference

Drug discovery group Summit Corporation PLC (LON:SUMM) said it is presenting the recently reported positive results from its programme targeting Alzheimer's disease and other neurological disorders at the Alzheimer's Association International Conference 2011 (ICAD 2011) which is currently being held in Paris.

Alzheimer's is a progressive and debilitating neurodegenerative disorder and is the most common form of dementia.  It remains an area of high unmet medical need with current treatment options only providing symptomatic relief. 

The presentation will highlight Summit's focus on a new and potentially disease modifying strategy for the treatment of Alzheimer's disease that targets the enzyme OGA (O-linked N-acetylglucosaminidase).

The company identifid and then optimised the generation of extremely potent, selective and non-cytotoxic inhibitors of OGA using its Seglin technology drug discovery platform.

Summit will also demonstrate in a human cellular model that the Seglin OGA inhibitors reduce levels of an abnormal form of the protein Tau, found in the brain of Alzheimer's patients and which causes the formation of toxic 'tangles' and ultimately results in disease symptoms.

Interest in the Tau protein as an approach for developing drugs to treat Alzheimer's disease continues to increase as evidenced by the growing number of peer-reviewed scientific publications, Summit said.

“As results from Summit's early-stage programme show, inhibition of OGA by Seglins can reduce the levels of hyperphosphorylated Tau and potentially offers a new strategy for treating this disease,” it added.

View full SUMM profile

Summit Therapeutics PLC Timeline

Related Articles

drug resistant infections such as E. coli and Pseudomonas
October 02 2016
In vivo testing confirmed that Redx’s novel compounds were highly effective against certain drug resistant strains of bacteria.
A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
shutterstock_234586750.jpg
October 24 2016
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.